Question · asked by 1 review
Dental examinations at three-month intervals and preventive treatments vs usual care: MRONJ (incidence rate: cases per patient-year)
- Population
- Men with metastatic prostate cancer receiving intravenous zoledronic acid (at risk of MRONJ)
- Intervention
- Dental examinations at three-month intervals and preventive treatments
- Comparison
- usual care
- Outcome
- MRONJ (incidence rate: cases per patient-year)
It is very uncertain whether dental examinations at three-month intervals and preventive treatments changes MRONJ (incidence rate: cases per patient-year) compared with standard care (very low certainty).
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Dental examinations at three-month intervals and preventive treatments vs Standard care MRONJ (incidence rate: cases per patient-year) · Men with metastatic prostate cancer receiving intravenous zoledronic acid (at risk of MRONJ) · mean 28.8 months It is very uncertain whether dental examinations at three-month intervals and preventive treatments changes MRONJ (incidence rate: cases per patient-year) compared with standard care (very low certainty). Interventions for managing medication‐related osteonecrosis of the jaw (2022) · Cochrane All outcomes | rate ratio 0.18 [0.04, 0.74] | 1 study · 253 participants | Very low |
Dental examinations at three-month intervals and preventive treatments vs Standard care MRONJ (incidence rate: cases per patient-year) · Men with metastatic prostate cancer receiving intravenous zoledronic acid (at risk of MRONJ) · mean 28.8 months Dental examinations at three-month intervals and preventive treatments may leads to lower MRONJ (incidence rate: cases per patient-year) compared with standard care (low certainty). Interventions for managing medication‐related osteonecrosis of the jaw (2017) · Cochrane All outcomesearlier version CD012432.PUB2, superseded | rate ratio 0.18 [0.04, 0.74] | 1 study · 253 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing medication‐related osteonecrosis of the jaw 2022 · Cochrane All outcomes | 2021-06 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.